Roche's Genentech picked up FDA approval for its late-stage breast cancer therapy Kadcyla, formerly T-DM1, which uses antibodies to deliver cancer drugs directly to the offending cells.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Roche has gained the inside track in the final lap of a long and expensive race to win an FDA approval for the armed antibody T-DM1, a new approach to treating HER2-positive breast cancer that marks a significant advance for patients.
Roche and ImmunoGen's trastuzumab emtansine (T-DM1) slashed the risk of death by almost a third compared with standard treatment in the EMILIA Phase III trial in women with advanced breast cancer.
Investigators behind the big T-DM1 breast cancer program took the lid off the last big data box from its pivotal study this morning, revealing that the armed antibody delivered a 32% reduction in the risk of death among patients in the pivotal Phase III study when compared to the standard-of-care arm.
ImmunoGen's ($IMGN) antibody-drug conjugate (ADC) trastuzumab emtansine (T-DM1) has significantly improved survival in a Phase III trial in women with advanced breast cancer, and the agent has been submitted for marketing approval.
A Cowen & Company analyst argued Wednesday that investors haven't given much credit to ImmunoGen's other drug candidates, and his assessment preceded a bump in the company's stock price.
Mersana Therapeutics has raised $27 million in a Series A-1 financing led by new investor New Enterprise Associates (NEA), and will use the money to continue development of its Fleximer antibody-drug conjugate (ADC) platform and other ADCs. This is the first biopharma investment from NEA's recently announced $2.6 billion NEA 14 fund.
The past year has been one worth celebrating for developers of antibody-drug conjugates (ADCs), which are drugs that marry an anti-cancer toxin to a targeted antibody to kill tumors with fewer side effects than traditional treatments.
The drug delivery company may not be worth the $1.2 billion its investors would believe.